Our Portfolio

Our platform

We are currently developing a platform of Pannexin 1 channel blockers optimized and specific for different therapeutic areas and indications, like CNS, cancer, inflammatory, cardiovascular, pulmonary etc.

Our portfolio

Currently we are working on our first target indication, which is chronic pain / opioid addiction, but we will select during 2022 additional three potential target indications.

Partner with us

Pannexin 1 channel blockers have a potential in many therapeutic areas, we are open to partner therapeutic areas or indications.

Contact us